about
Fibrin degradation product (FnDP) assays: analysis of standardization issues and target antigens in plasmaAssessing receptivity in the endometrium: the need for a rapid, non-invasive test.Phase II biomarker trial of a multimarker diagnostic for ovarian cancerFresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence.Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer.Proteomics of the human endometrium and uterine fluid: a pathway to biomarker discovery.The Microenvironment of Human Implantation: Determinant of Reproductive Success.The proliferative phase underpins endometrial development: Altered cytokine profiles in uterine lavage fluid of women with idiopathic infertility.The international standard for plasminogen activator inhibitor-1 (PAI-1) activity.The International and "NIH" units for thrombin--how do they compare?Assessment of potential biomarkers of pre-receptive and receptive endometrium in uterine fluid and a functional evaluation of the potential role of CSF3 in fertilityMonoclonal antibodies to human fibrin: interaction with other animal fibrinsDetection of fibrin in canine neoplasiaA pig collagen peptide fraction. A unique material for maintaining biological activity during lyophilization and during storage in the liquid stateStability of the glyco-enzyme tissue plasminogen activator studied by circular dichroismSoluble fibrin. Characterisation and assay proceduresFibrin polymerisation. Evidence for a secondary polymerisation site on the carboxy terminal end of the AA chain using a human fibrin specific murine monoclonal antibodyThe Second British Standard for batroxobin (moojeni)Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancerDevelopment of a high-throughput assay for human proprotein convertase 5/6 for detecting uterine receptivitySoluble Delta-like ligand 1 alters human endometrial epithelial cell adhesive capacityIdiopathic infertility in women is associated with distinct changes in proliferative phase uterine fluid proteins
P50
Q28303518-3617134B-43A6-49F9-B6E0-BD0951C2EFB3Q30221696-032A5CB3-902E-4F5D-864E-F4D5DD80E480Q33868802-4AC6DC69-3F96-4839-B22D-9EB338600978Q34424029-A5F9F140-7B1A-47E4-BE36-537078BA47EBQ35180145-F2A6F3F0-98CF-488A-A333-8C8BFDD926BAQ38050203-C5452E37-9083-4913-87C7-66045EE9E894Q38667804-6B2E7A18-1ABC-407C-97B4-F8138CB511E8Q51571284-D638D533-77C6-4C4A-9C42-FBAC18AF846DQ53366743-F917AA09-13AE-44A5-894C-7A14A4CF7B2CQ53373233-7C9630BC-4B9E-48EF-B6F5-6DA25311EDF7Q57160560-B5276A6B-D568-491E-BB29-F1C9C1321558Q62726837-8C7DE6A4-9D7A-4BCF-8FD6-667A07BE7ACAQ62726839-5B6999CC-E16B-49A5-963A-BDC480410241Q71763831-6ACF5144-0B9C-4264-A466-F23192AE7D5FQ72257760-DA9F74F3-28D5-495E-9AC3-1648A0006A50Q73518016-CB53DF25-E9E0-4C36-B6FB-963EAB1F65CAQ73518022-681B8E10-CAEC-49FE-9007-469ADFBCE7F4Q77737203-61FDE81D-6178-45AA-B99D-67A85A4DB15CQ82804658-5F38C1C1-94A8-458F-9EB3-376CEDAD2987Q86442544-46060AB2-8463-43B4-9EBF-D193D2254453Q86827485-FDA6ADB7-8DA8-421B-A1E3-A160E32E08CFQ88075679-002E79C8-0E24-4DC8-918A-2ACF9B5069F3
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tracey Edgell
@ast
Tracey Edgell
@en
Tracey Edgell
@es
Tracey Edgell
@nl
type
label
Tracey Edgell
@ast
Tracey Edgell
@en
Tracey Edgell
@es
Tracey Edgell
@nl
prefLabel
Tracey Edgell
@ast
Tracey Edgell
@en
Tracey Edgell
@es
Tracey Edgell
@nl
P106
P31
P496
0000-0002-5262-9949